Latest news with #HodgkinsLymphoma
Daily Mail
3 days ago
- General
- Daily Mail
Uni student Maddie, 19, felt something unusual on her neck - then a quick Google search led to the unthinkable
Maddie King was a healthy 19-year-old university student preparing for the adventure of a lifetime: a semester abroad in Los Angeles. When she began noticing hard lumps in her neck, she had no idea her body was quietly battling a rare form of cancer that had gone undetected for years. Her whole world turned upside when she was diagnosed with stage four Hodgkin's lymphoma, the most advanced form of blood cancer. 'By the time they found it, it was all through my neck and chest, including a 9cm tumour in my lungs,' Maddie, now 25, told FEMAIL. It started with a cough, some mild night sweats, and the discovery of a few mysterious lumps - symptoms that, on their own, didn't seem urgent. 'I didn't have any idea anything was wrong until about three months before my diagnosis. I'd never noticed the lumps before, but they must have been growing for years,' she said. At first, her doctors in Sydney were unsure because scans and biopsies came back inconclusive. She was prescribed antibiotics for what they suspected was pneumonia, but Maddie had a nagging feeling that something wasn't right. 'I was Googling everything. And eventually, it all started pointing to cancer. I was hoping it was something else - tuberculosis, a lung infection - anything but that,' she said. She left for the US with a suitcase full of medical records and a sense of unease. It was the university doctor in LA who finally urged her to take urgent action: 'You need to fly home and get an excision biopsy.' She returned to Sydney in October 2019. Days later, she had a formal diagnosis. 'The diagnosis actually came as a relief,' Maddie admitted. 'After months of not knowing, I could finally make a plan.' But there was no time to process what was happening - almost immediately, she was thrown into a whirlwind of appointments with haematologists, oncologists and even fertility specialists. 'They talked about fertility on the day of diagnosis. Within a week, I was doing IVF injections to preserve some eggs before chemo,' she said. The treatment was brutal : six rounds of intense chemotherapy, followed by a month of radiation. For months, her life was consumed by blood tests, back-to-back medication schedules, isolation, and relentless cycles of pain. 'Chemo completely rips away any sense of normality. You can't plan your day. You can't see friends. You're immunocompromised. I was wearing masks before COVID was even a thing,' she said. Her academic life paused - she took a year off from university. Her social life dwindled. She was often too exhausted to leave the house, let alone think about being 19 and carefree. 'It's a very lonely and disorienting time. Everything changes overnight,' she said. Maddie's journey wasn't just a physical battle, it was an emotional and psychological one, too. At an age when most of her peers were starting internships, going on holidays, or dating freely, she was navigating oncology wards and hormone injections. She remembers trying to distract herself in those early days, trying not to fall apart. 'It was messy. I didn't have the tools back then to process it. I just tried to keep going.' She leaned heavily on her then-boyfriend and her mother, who stayed by her side through the testing, treatment and uncertainty. Maddie's story is made even more heartbreaking by a devastating family history. At 16, she lost her father to pancreatic cancer - a diagnosis that left little time for treatment. 'He was diagnosed and passed away within a month. He didn't even have chemo, it was just about managing the pain. Our experiences couldn't have been more different,' she recalled. When she got her own diagnosis just three years later, it stirred up complicated emotions. 'It was confusing. Part of me was relieved he didn't have to watch me go through it. No parent should have to see their child go through chemo. But part of me wished he was there - I think he would've been proud,' she said. In March 2025, Maddie celebrated a milestone many cancer survivors dream of: five years in remission. 'I went to Vietnam with my partner to celebrate. It was beautiful,' she said. She no longer needs regular scans, but she remains vigilant with GP check-ups and bloodwork. Chronic health issues still linger, a reminder that the battle didn't end when the treatment did. But she's learning to live alongside them with grace, strength and gratitude. Looking back, she says her journey taught her a painful but profound truth: No one is too young. No one is too healthy. Cancer doesn't care. But neither, she adds, should we underestimate the power of small acts of care such as a Facebook message, a meal, or a $10 donation, to help someone who is fighting for their life. Maddie revealed that it was a community of strangers - young women going through similar diagnoses - who helped her feel less alone. 'During the whirlwind of medical appointments, I found Rikki and Cancer Chicks,' Maddie says, referring to founder Rikki Stern, who launched the community to support young women with cancer after being diagnosed with Stage 2B Hodgkin's Lymphoma at 19. 'I just found her on social media. She invited me to join the Facebook group. When I introduced myself and shared my story, the outpouring of support was unbelievable.' From questions about side effects to decoding confusing scan results, Cancer Chicks became a lifeline, offering real-time advice, empathy, and hope. 'I was in chemo when I went to their first retreat. I didn't have eyebrows, and they ran a workshop on how to draw them on. It sounds small, but it made me feel human again.' The community gave Maddie a glimpse into the future - a future where women like her survived, healed, and rebuilt their lives. 'We're a small subset of the population - young women with cancer - but Cancer Chicks makes you feel seen. That someone cares. That you're not forgotten.' Now healthy and working in marketing at a Sydney startup called Magic Brief, Maddie is passionate about giving back. By sharing her story, she hopes to raise awareness for young Aussies going through cancer and highlight the power of female-driven support networks like Cancer Chicks - the community that helped her through her darkest days. She's especially excited about a new partnership between Cancer Chicks and Afterpay, which allows people to donate in instalments, making generosity more accessible in the current cost-of-living crisis. 'People always ask me where they can donate, but they think they need to give $100 or $500 to make an impact. That's just not true,' she explained. Some of the most meaningful gestures Maddie received during treatment weren't grand - they were practical. 'Ready meals, a $15 UberEats voucher, little things like that completely changed my day,' she said. With the Afterpay model, donors can contribute manageable amounts over time - helping charities like Cancer Chicks fund retreats, events, and workshops that provide direct, tangible support.
New York Times
16-05-2025
- Health
- New York Times
Raiders rookie OT Charles Grant more than a small-school prospect: ‘He's truly special'
William & Mary football coach Mike London was an assistant at Boston College in 2000 when he learned that his daughter, Ticynn, was diagnosed with Fanconi anemia, a rare blood disorder that can lead to cancer and bone marrow failure. London and his wife sought a match through the National Marrow Donor Program but couldn't find one. Advertisement London had his other children tested, but they weren't a match, either. With desperation setting in, London and his wife got tested. London came up as a match, and he and Ticynn underwent a transplant in 2003 that ultimately saved her life. The experience moved London to lead and participate in bone marrow drives throughout his coaching career. When he brought it up during spring practice in 2022, a young offensive lineman named Charles Grant was quick to add his name to the national bone marrow registry. Grant went on to become a starter at left tackle that season. He played well enough to land on the radar of NFL scouts. 'That was when the thought was like, 'I can actually do this,'' Grant said last month. 'It's something that I grabbed and just tried to strive for.' Then, in May 2023, he was notified that he had been identified as a match for a Hodgkin's lymphoma patient. He called the coaching staff to notify them that he'd be following through as a donor. 'When they called him and said, 'Hey, you're a match,' there was no hesitation,' former William & Mary offensive line coach Mario Acitelli said recently. 'It wasn't like, 'Oh, well, let's see what kind of procedure it would need to be to determine if I'm going to do it.' It was like, 'I can save somebody's life? Hell yeah, I'm doing it.'' Grant underwent a successful peripheral blood stem cell donation shortly after. His taking the time to do that, even as he aspired to play in the NFL, resonated with William & Mary players and coaches alike. 'I tell you what, man, you're talking to a guy that saved his daughter's life, and when you get a guy like that,' London said Tuesday before taking a moment to gather his emotions. 'That's a big-time deal. It's a character thing that I see in him. He's truly special. I love the guy because of what he stands for.' This offseason, under general manager John Spytek and coach Pete Carroll, the Las Vegas Raiders placed an increased emphasis on character when deciding whether a player was worth adding to the team. As much as Grant's 6-foot-5, 309-pound frame, exceptional athleticism, uncommon movement skills and ability to manhandle defenders got their attention in the draft process, so did who he was as a person. Advertisement 'He's a man of high character,' London said. 'I'm so proud of him, of what he's done and what he's still yet to do.' The top-30 visit Grant took to Raiders headquarters leading up to the draft confirmed he was the total package. And when Grant was still on the board at pick No. 99 in the third round, the Raiders didn't hesitate. 'A good athlete and a good person,' Spytek said last month. 'He can really move his feet and run into space. (Offensive coordinator) Chip (Kelly) is super fired up about getting him in there. He fits the scheme great.' Grant is aware of the negative stigma often attached to prospects from small schools like William & Mary, an FCS program. There's typically some doubt they'll be able to cut it against NFL-level talent. While Grant acknowledges it'll be a steep uptick in competition, he believes he can silence the skeptics. 'I have a chip on my shoulder,' Grant said. 'I know what I can do. I've just got to prove it to everybody.' day one @CharlesGrant51#TribeInTheNFL | #RaiderNation 📸 @Raiders — William & Mary Tribe Football (@WMTribeFootball) May 10, 2025 Grant didn't play sports until he picked up wrestling in seventh grade, and he didn't play football until he was a junior at Churchland High in Portsmouth, Va. The coaching staff put him at left tackle and, while he was raw, he showed some early flashes that he attributed to his wrestling background. '(It was) the mental fortitude. It takes a lot to go out on the mat and just keep doing it even when you're dog tired,' Grant said. '(You have to) just keep fighting and finishing the match. … I used to wrestle for like four hours a day. I know I can persevere through anything I've been going through. … And I'd also say my ability to move off the ball, be quick, be nimble and cut the backside off, just things like that. I knew how to position my body.' Advertisement Nonetheless, Grant remained a no-star recruit. He weighed just 240 pounds and hadn't participated in many camps since he continued to wrestle. He landed a Division II offer from Virginia-Wise following his junior season, and his only Division I offer came from William & Mary. Grant committed to William & Mary at the start of his senior year. He received more offers after earning first-team all-region honors that season but stuck with his pledge since William & Mary is less than an hour from his hometown and the Tribe staff showed faith in him early. 'He was an offensive lineman that had some growth and development still left to do,' London said, 'but he had measurables, he was athletic and he had a great attitude.' When Grant enrolled in 2020, his first order of business was bulking up. Even at the FCS level, 240 pounds wouldn't cut it at offensive tackle. He redshirted as a freshman and spent that time improving his physique, refining his technique and working on the team's zone-based blocking scheme. Grant progressed enough to start five games the next season, but the real turning point came in 2022. William & Mary was down to just five scholarship offensive linemen, and then one got hurt in fall camp. That put more pressure on Grant to step up. Grant started every game that season, and then did the same in 2023 on his way to being named a first-team FCS All-American. 'The confidence level (went up),' Acitelli said. 'Once he knew, 'Hey, I can be good at this and I can be dominant,' it really started to take off.' Thank you!! — Charles Grant (@CharlesGrant51) April 29, 2025 Following that breakout 2023 season, Grant had several opportunities to leave William & Mary for a bigger program. FBS teams attempted to poach him with lucrative NIL offers. 'There were some teams that offered him a lot of money to forgo his last year here and go to their place,' London said. Grant knew William & Mary wouldn't be able to match those deals, but he turned them down anyway. The biggest reason Grant stuck with the Tribe was the connection he had with his teammates over four years. They voted to name him a team captain, and he went on to have his best collegiate season as he was again named a first-team FCS All-American. Advertisement 'William & Mary had given him an opportunity, and he wanted to make sure he finished it with those guys,' Acitelli said. 'He was dominant. I mean, he was throwing guys around and knocking guys down on an almost play-by-play basis. He was cutting guys off. We never had to worry about, 'Yeah, if we run the ball to the right, is he going to be able to cut off the 4i or the three technique?' That wasn't an issue. And then we knew when we ran to this side, there was going to be movement on the front side. It was a pretty awesome deal. … 'I moved from offensive line (coach) to offensive coordinator last year. I still coached the offensive line, but then on game day, I was trying to do two different things. … It forced (Grant) to become even more of a leader on game day and be more vocal.' .@WMTribeFootball @CharlesGrant51 what a fascinating prospect. Great length; Great feet; lots of action. Good coaching; more strength and we have a starting tackle in the NFL #nfldraft #BaldysBreakdowns — Brian Baldinger (@BaldyNFL) April 20, 2025 London compared Grant to a smaller version of former NFL offensive tackle D'Brickashaw Ferguson, who was drafted fourth overall in 2006 and went on to become a three-time Pro Bowl selection. That's a lofty expectation, and Grant has plenty to work on before he gets there. Most notably, Grant remains light for a left tackle. He needs to continue getting stronger and adding mass. Without that, he won't be able to anchor and handle the more powerful rushers in the NFL. Concerns about his size, the consistency of his technique, coming from an FCS program and a late-season knee injury that rendered him unable to participate in the Senior Bowl or test at the combine hurt his draft stock. The Raiders drafted him even though there isn't a clear path to immediate playing time with Kolton Miller entrenched at left tackle. It'd be more feasible for Grant to compete with DJ Glaze at right tackle, but switching sides isn't as easy and requires a significant amount of mental and physical adjustments. The Raiders plan to cross-train him to see if he can pull it off. 'We do not hold them back and keep them out of the fire,' Carroll said. 'We're going to put them in there right away and let them see where they stack up.' Advertisement Something that'll help Grant is that he's a good fit for Kelly's system, which utilizes a zone-based blocking scheme similar to the one he played in at William & Mary. That and his unique combination of traits will give him a shot to compete for a role early on. 'I have great athletic ability,' Grant said, 'but if I can put the perfect technique to that, I know I'd become a player that's unstoppable.'
Globe and Mail
15-05-2025
- Business
- Globe and Mail
Hodgkin's Lymphoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Hodgkin's Lymphoma Pipeline Insight 2025' report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hodgkin's Lymphoma pipeline landscape. It covers the Hodgkin's Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hodgkin's Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Hodgkin's Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Hodgkin's Lymphoma Pipeline Outlook Key Takeaways from the Hodgkin's Lymphoma Pipeline Report In May 2025, Celgene announced a phase II study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. In May 2025, Hoffmann-La Roche conducted a Phase I/II study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. In May 2025, Bristol-Myers Squibb organized a study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. DelveInsight's Hodgkin's Lymphoma Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin's Lymphoma treatment. The leading Hodgkin's Lymphoma Companies such as Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others. Promising Hodgkin's Lymphoma Pipeline Therapies such as HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others. Stay ahead with the most recent pipeline outlook for Hodgkin's Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hodgkin's Lymphoma Treatment Drugs Hodgkin's Lymphoma Emerging Drugs Profile AFM 13: Affimed Therapeutics AFM13 is a first-in-class innate cell engager (ICE®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is most advanced ICE® clinical program and was evaluated as monotherapy in a Phase IIB trial in patients with relapsed/refractory peripheral T cell lymphoma (REDIRECT). The study achieved an ORR of 32.4% demonstrating anti-tumor activity with a DOR of 2.3 months and a well-managed safety profile. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. Currently it is in Phase II stage of clinical trial evaluation to treat Hodgkin's Lymphoma. AUR105 : Aurigene Oncology AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications like solid tumor, non-Hodgkin lymphoma, leukemia or Hodgkin lymphoma. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I for the treatment of Hodgkin's Lymphoma. The Hodgkin's Lymphoma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin's Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin's Lymphoma Treatment. Hodgkin's Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin's Lymphoma market Explore groundbreaking therapies and clinical trials in the Hodgkin's Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Hodgkin's Lymphoma Drugs Hodgkin's Lymphoma Companies Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others. Hodgkin's Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral intravenous Subcutaneous Topical Hodgkin's Lymphoma Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Unveil the future of Hodgkin's Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hodgkin's Lymphoma Market Drivers and Barriers Scope of the Hodgkin's Lymphoma Pipeline Report Coverage- Global Hodgkin's Lymphoma Companies- Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others. Hodgkin's Lymphoma Pipeline Therapies- HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others. Hodgkin's Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hodgkin's Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Hodgkin's Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hodgkin's Lymphoma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Hodgkin's Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Hodgkin's Lymphoma – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid-Stage Products (Phase II) AFM13: Affimed Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) AUR105 : Aurigene Oncology Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Hodgkin's Lymphoma Key Companies Hodgkin's Lymphoma Key Products Hodgkin's Lymphoma- Unmet Needs Hodgkin's Lymphoma- Market Drivers and Barriers Hodgkin's Lymphoma- Future Perspectives and Conclusion Hodgkin's Lymphoma Analyst Views Hodgkin's Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
21-02-2025
- Health
- Yahoo
‘You are always fighting the disease:' Cancer survivors face long-term health consequences years after treatment
We're in the midst of a cancer crisis. More young people being diagnosed. And while the treatments can be life-saving, years later they are life-altering. Tina Chip is a two-time cancer survivor having fought the disease twice in her life. Dr James Flaherty is an interventional cardiologist with Bluhm Cardiovascular Institute. 'Those that have come out of that experience often manifest cardiac problems 20, 30 years later,' he said. More from Med Watch: Research shows resiliency of newborns' hearts and what it could mean for adults For Chip, 30-plus years later, it's the aortic valve. Its function compromised by cancer treatment she received in 1989. 'I was 16, a senior in high school and just super excited to have that fun year and I felt a lump in my neck,' she said. That lump was Hodgkins Lymphoma. 'So I went every day for four months and received the radiation from pretty much my entire body,' she said. Just six years later, another cancer diagnosis. Breast cancer caused by the very treatment – radiation to her chest wall — that cured her Hodgkins. 'So very advanced disease,' she said. 'I was 22, just finishing college and not in the plan of what I wanted to do for my future.' More Coverage: WGN's Medical Watch The future for childhood and young adult cancer survivors is the potential for what doctors call the late effects of radiation and chemotherapy. Dr Aarati Didwania is an internal medicine physician with Northwestern Medicine. 'I can't take away the therapies they received, nor would I want to because it helped cure them, put them in remission. But I would like to try to find things before they become a problem,' Didwania said. That's where STAR comes in – Survivors Taking Action and Responsibility. Through the program at Northwestern Medicine, doctors monitor for liver, kidney and thyroid malfunction; secondary skin and breast cancers; and blood and heart abnormalities. Karen Kinahan is a nurse practitioner with Northwestern Medicine. 'So we end up getting a lot of patients, sometimes in their 40s even 50s, that have not been in a pediatric survivor program because there wasn't one for them and now they have had a medical consequence,' she said. 'I've survived cancer as a young adult and now I'm going to make sure I stay on top of everything else my body may give into,' Chip said. More News, Weather and Headlines at For the mother of three, the fight is far from over. 'My aortic valve is part of the area that would have gotten hit by the radiation and also possibly chemo long-term effects,' she said. 'And as time progresses, my valve isn't pumping blood out to the rest of my body.' 'We did what's known as an aortic valve study,' Flaherty said. 'We went across the aortic valve and measured the pressure below it and above it, in the left ventricle and the aorta to see how much narrowing or pressure drop there was across that valve.' 'Even though you are further away, and you think it was so far in the past that (you) don't have to worry about recurrence or late effects, it's actually as we get further away, age also plays a factor into that,' Didwania said. As survivors age – thanks to effective treatments — so does their tissue that was damaged long ago. Only exacerbating potential problems. 'It means we have a bigger survivorship population. There are more people surviving,' Didwania said. 'It's bad because there are more effects we have to look out for, and we have to train providers to be aware of these things and to know when and how to look for them.' Doctors will continue to monitor Chip's heart. Eventually, she'll likely require a valve repair. 'You have to become your own advocate and fight for yourself and know that this is now part of your life,' she said. 'You are always fighting the disease.' Radiation has changed since her treatment, more targeted and precise, in some cases lower doses. Still, even patients diagnosed and treated today will likely be at risk 20 or 30 years from now. Knowledge is power. You can learn more about the STAR program here. Sign up for our Medical Watch newsletter. This daily update includes important information from WGN's Dina Bair and the Med Watch team, including, the latest updates from health organizations, in-depth reporting on advancements in medical technology and treatments, as well as personal features related to people in the medical field. Sign up here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
